LINACS

Reference

Drug Index

143 drugs listed — 38 with available data. Greyed out = no data yet.

Drug category

Monoclonal Antibodies (mAbs) Targeted Therapy Antibody-Drug Conjugates (ADCs) Immunotherapy Gene Therapy

A B C D E F G I L M N O P R S T U V Z

Abemaciclib

CDK4/6 inhibitor

Adagrasib

KRAS Inhibitors

Afamitresgene Autoleucel

CAR-T or Cell Therapy

Afatinib

EGFR targeting TKI

Aflibercept

VEGF-trap

Alectinib

ALK targeting TKI

Alpelisib

PI3K inhibitor

Amivantamab

anti-EGFR/MET mAb

Apatinib

VEGFR targeting TKI

Atezolizumab

Anti-PD-(L)1 mAb

Avapritinib

Multi-target TKI

Avelumab

Anti-PD-(L)1 mAb

Avutometinib

RAF–MEK clamp

Axitinib

Multi-target TKI

Belzutifan

HIF-2α inhibitor

Bevacizumab

VEGF mAb

Binimetinib

MEK inhibitor

Brigatinib

ALK targeting TKI

Cabiralizumab

anti-CSFR mAb

Capivasertib

AKT inhibitor

Capmatinib

MET targeting TKI

Catumaxomab

BiTE

Cemiplimab

Anti-PD-(L)1 mAb

Cobimetinib

MEK inhibitor

Cosibelimab

Anti-PD-(L)1 mAb

Crizotinib

Multi-target TKI

Dabrafenib

BRAF inhibitor

Dacomitinib

EGFR targeting TKI

Datopotamab Deruxtecan

ADC

Defactinib

FAK/Pyk2 inhibitor

Denosumab

Anti-RANKL mAb

Dinutuximab

anti-GD2 mAb

Dordaviprone

ClpP protease activator

Dostarlimab

Anti-PD-(L)1 mAb

Durvalumab

Anti-PD-(L)1 mAb

Encorafenib

BRAF inhibitor

Enfortumab Vedotin

ADC

Ensartinib

ALK targeting TKI

Entrectinib

Multi-target TKI

Erdafitinib

FGFR targeting TKI

Fruquintinib

VEGFR targeting TKI

Futibatinib

FGFR targeting TKI

Inavolisib

PI3K inhibitor

Infigratinib

FGFR targeting TKI

Ipilimumab

Anti-CTLA-4 mAb

Ivosidenib

IDH inhibitor

Lanreotide

Somatostatin analog

Lapatinib

Multi-target TKI

Larotrectinib

TRK targeting TKI

Lifileucel

CAR-T or Cell Therapy

Lorlatinib

ALK targeting TKI

Margetuximab

anti-HER2 mAb

Mifamurtide

immunotherapy NOS

Mirvetuximab Soravtansine

ADC

Mobocertinib

EGFR targeting TKI

Mogamulizumab

anti-CCR4 mAb

Nab-Sirolimus

mTOR

Nadofaragene Firadenovec

Gene Therapy

Naxitamab

anti-GD2 mAb

Necitumumab

Anti-EGFR mAb

Neratinib

HER(2) targeting TKI

Nilotinib

Multi-target TKI

Nintedanib

Multi-target TKI

Niraparib

PARP inhibitor

Nirogacestat

Gamma-secretase inhibitor

Nivolumab

Anti-PD-(L)1 mAb

Nogapendekin alfa inbakicept

immunotherapy NOS

Panitumumab

Anti-EGFR mAb

Pazopanib

Multi-target TKI

Peginterferon Alfa-2b

immunotherapy NOS

Pembrolizumab

Anti-PD-(L)1 mAb

Pemigatinib

FGFR targeting TKI

Penpulimab

Anti-PD-(L)1 mAb

Pertuzumab

anti-HER2 mAb

Pertuzumab + hyaluronidase

anti-HER2 mAb

Pertuzumab + trastuzumab + hyaluronidase

anti-HER2 mAb

Pralsetinib

RET targeting TKI

Racotumomab

Anti-idiotype vaccine mAb

Ramucirumab

VEGF mAb

Regorafenib

Multi-target TKI

Relatlimab

Anti-LAG-3 mAb

Repotrectinib

Multi-target TKI

Retifanlimab

Anti-PD-(L)1 mAb

Ribociclib

CDK4/6 inhibitor

Ripretinib

Multi-target TKI

Rucaparib

PARP inhibitor

Ruxolitinib

JAK inhibitor

Sacituzumab Govitecan

ADC

Selpercatinib

RET targeting TKI

Serplulimab

Anti-PD-(L)1 mAb

Sevabertinib

HER(2) targeting TKI

Sintilimab

Anti-PD-(L)1 mAb

Sipuleucel-T

immunotherapy NOS

Sonidegib

Hedgehog Pathway Inhibitors

Sorafenib

Multi-target TKI

Sotorasib

KRAS Inhibitors

Sugemalimab

Anti-PD-(L)1 mAb

Sunitinib

Multi-target TKI

Sunvozertinib

EGFR targeting TKI

Talazoparib

PARP inhibitor

Taletrectinib

ROS1 targeting TKI

Talimogene Laherparepvec

immunotherapy NOS

Tarlatamab

BiTE

Tazemetostat

EZH2 inhibitor

Tebentafusp

BiTE

Telisotuzumab vedotin

ADC

Temsirolimus

mTOR

Tepotinib

MET targeting TKI

Tislelizumab

Anti-PD-(L)1 mAb

Tisotumab Vedotin

ADC

Tivozanib

VEGFR targeting TKI

Toripalimab

Anti-PD-(L)1 mAb

Tovorafenib

BRAF inhibitor

Trametinib

MEK inhibitor

Trastuzumab

anti-HER2 mAb

Trastuzumab Deruxtecan

ADC

Trastuzumab Emtansine

ADC

Tremelimumab

Anti-CTLA-4 mAb

Tucatinib

HER(2) targeting TKI

Urelumab

CD137 agonist mAb

Vandetanib

Multi-target TKI

Vemurafenib

BRAF inhibitor

Vimseltinib

CSFR1 targeting TKI

Vismodegib

Hedgehog Pathway Inhibitors

Vorasidenib

IDH inhibitor

Zanidatamab

anti-HER2 mAb

Zenocutuzumab

anti-HER2 mAb

Zolbetuximab

anti-claudin 18.2 mAb

Zongertinib

HER(2) targeting TKI